NCT02973594View on ClinicalTrials.gov

Pulse Reduction On Beta-blocker and Ivabradine Therapy

PHASE4CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

November 30, 2016

Primary Completion Date

December 31, 2022

Study Completion Date

June 30, 2023

Conditions
Dilated Cardiomyopathies, IdiopathicHeart Failure, SystolicVentricular RemodelingElectrical Remodeling
Interventions
DRUG

Ivabradine

DRUG

Placebo

Trial Locations (2)

43210

The Ohio State University Wexner Medical Center, Columbus

80045

University of Colorado Anschutz Medical Campus, Aurora

All Listed Sponsors
collaborator

American Heart Association

OTHER

collaborator

Ohio State University

OTHER

lead

University of Colorado, Denver

OTHER

NCT02973594 - Pulse Reduction On Beta-blocker and Ivabradine Therapy | Biotech Hunter | Biotech Hunter